Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29474880 | 1.00 | SCN3A (0.52) | SCN3AMEN1KMT2APRCPSMYD3 | |
| SCHEMBL32677003 | 1.00 | SCN3A (0.52) | SCN3AMEN1KMT2APRCPSMYD3 | |
| SCHEMBL32677100 | 1.00 | SCN3A (0.52) | SCN3AMEN1KMT2APRCPSMYD3 | |
| SCHEMBL1509610 | 1.00 | SCN3A (0.52) | SCN3AMEN1KMT2APRCPSMYD3 | |
| Hydrochloric Acid SCHEMBL30225627 | 0.98 | MEN1 (0.51) | SCN3AMEN1KMT2APRCPSMYD3 | |
| Hydrochloric Acid SCHEMBL29897791 | 0.98 | MEN1 (0.51) | SCN3AMEN1KMT2APRCPSMYD3 | |
| Hydrochloric Acid SCHEMBL27787267 | 0.98 | MEN1 (0.51) | SCN3AMEN1KMT2APRCPSMYD3 | |
| Hydrochloric Acid SCHEMBL4787147 | 0.98 | MEN1 (0.51) | SCN3AMEN1KMT2APRCPSMYD3 | |
| SCHEMBL288272 | 0.83 | GAA (0.58) | MEN1KMT2APRCPPNMTOPRM1 | |
| SCHEMBL288260 | 0.83 | GAA (0.58) | MEN1KMT2APRCPPNMTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B8 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| EP-0751128-B2 | Process for producing optically active amides | AJINOMOTO KK (JP) | 2005-08-31 | — | — | EP | claimed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| EP-0751128-B1 | Process for producing optically active amides | AJINOMOTO KK (JP) | 1999-07-28 | — | — | EP | claimed |
| EP-0751128-A1 | Process for producing optically active amides | Ajinomoto Co., Ltd. (JP) | 1997-01-02 | — | — | EP | claimed |
| US-12503455-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230312520-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| EP-3717009-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | Arrakis Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111386127-A | Nucleic acid-binding light probes and uses thereof | 阿拉基斯医疗公司 | 2020-07-07 | — | — | CN | disclosed |
| US-5994545-A | TETRAHYDROISOQUINOLINE-3(S)-CARBOXYLIC ACID N-CARBOXY ANHYDRIDE; INTERMEDIATES OF SAQUINAVIR (EP 432694). | AJINOMOTO CO., INC. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5994545-A | TETRAHYDROISOQUINOLINE-3(S)-CARBOXYLIC ACID N-CARBOXY ANHYDRIDE; INTERMEDIATES OF SAQUINAVIR (EP 432694). | AJINOMOTO CO., INC. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0751128-B1 | Process for producing optically active amides | AJINOMOTO KK (JP) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999028313-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| EP-0751128-A1 | Process for producing optically active amides | Ajinomoto Co., Ltd. (JP) | 1997-01-02 | — | — | EP | disclosed |
| EP-0751128-A1 | Process for producing optically active amides | Ajinomoto Co., Ltd. (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312520-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | NSUN3, NSUN2, TARBP1 | SCN3A 4664/4885MEN1 4474/4885KMT2A 2159/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | SCN3A 1706/4885MEN1 1339/4885KMT2A 1330/4885 |
| US-12503455-B2 | Nucleic acid-binding photoprobes and uses thereof | NSUN3, NSUN2, TARBP1 | SCN3A 4664/4885MEN1 4474/4885KMT2A 2159/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | SCN3A 1459/4885MEN1 1494/4885KMT2A 4121/4885 |
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | NSUN3, NSUN2, TARBP1 | SCN3A 4664/4885MEN1 4474/4885KMT2A 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.